Investigational drug · Phase 3
Centhaquine
Also called: PMZ-2010
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Respiratory Distress Syndrome (ARDS), Hypovolemic Shock.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "Centhaquine"
First trial start
2027
Feb 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Centhaquine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Respiratory Distress Syndrome (ARDS)
- Hypovolemic Shock
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Centhaquine" as an intervention, largest first.
- A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative AgentPivotal-lookingNot yet recruiting
Pharmazz, Inc.Industry
NCT05251181 · 430 participants (planned) · Start Feb 2027 · Primary completion Oct 2028
Drug: Normal Saline; Centhaquine · For: Hypovolemic Shock
Pharmazz, Inc.Industry
NCT05956418 · 400 participants (planned) · Start Aug 13, 2021 · Primary completion Nov 2026
Drug: Centhaquine · For: Hypovolemic Shock
Sites: Nellore, India; Raipur, India; Vadodara, India · 17 sites in all
- Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic ShockPivotal-lookingCompleted
Pharmazz, Inc.Industry
NCT04045327 · 105 participants · Start Jan 31, 2019 · Primary completion Sep 23, 2019
Drug: Normal saline + Standard Treatment; Centhaquine + Standard Treatment · For: Hypovolemic Shock
Sites: Nagpur, India; Ajmer, India; Amravati, India · 18 sites in all
- Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDSNot yet recruiting
Pharmazz, Inc.Industry
NCT05241067 · 80 participants (planned) · Start May 2027 · Primary completion Oct 31, 2027
Drug: Normal Saline; Centhaquine · For: Acute Respiratory Distress Syndrome (ARDS)
Pharmazz, Inc.Industry
NCT04056065 · 50 participants · Start May 29, 2017 · Primary completion Sep 19, 2018
Drug: Normal Saline; Centhaquine · For: Hypovolemic Shock; Blood Loss
Sites: Nagpur, India; Belagavi, India; Chandigarh, India · 7 sites in all
Pharmazz, Inc.Industry
NCT02408731 · 24 participants · Start Oct 2014 · Primary completion Apr 2015
Drug: PMZ-2010 (Centhaquin) · For: Healthy
Sites: Pune, India
Newest research
PubMed records naming it or its code names, newest first.
- Haemodynamic effects of selective venoconstriction with centhaquine in spontaneously breathing patients with mixed hypovolaemic-vasodilatory shock.
Chalkias A, Khanna A, Vaidya K, et al. · Exp Physiol 2026
- Emerging Therapeutics in Hypovolemic Shock With Centhaquine Citrate-A Novel Venopressor That Leverages the Alpha Receptor Family.
Augoustides JG · J Cardiothorac Vasc Anesth 2025
- Therapeutic Potential of Centhaquine Citrate, a Selective Alpha-2B Adrenoceptor Agonist, in the Management of Circulatory Shock.
Legrand M, Ranjan A, Rammohan S, et al. · Drugs 2025
- Centhaquine Increases Stroke Volume and Cardiac Output in Patients with Hypovolemic Shock.
Khanna A, Vaidya K, Shah D, et al. · J Clin Med 2024
- Effect of Centhaquine on the Coagulation Cascade in Normal State and Uncontrolled Hemorrhage: A Multiphase Study Combining Ex Vivo and In Vivo Experiments in Different Species.
Chalkias A, Pais G, Gulati A · Int J Mol Sci 2024
- Catalyst-free anti-Markovnikov hydroamination and hydrothiolation of vinyl heteroarenes in aqueous medium: an improved process towards centhaquine.
Yadav A, Ambule MD, Srivastava AK · Org Biomol Chem 2024
Also in development for Acute Respiratory Distress Syndrome (ARDS)
- STSA-1002Phase 32 trials
Staidson (Beijing) Biopharmaceuticals Co., Ltd · Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Distress Syndrome
- paridiprubartPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- vilobelimabPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- ALT-100Phase 21 trial
Aqualung Therapeutics Corp. · Acute Respiratory Distress Syndrome (ARDS)
- TISA-818-InjPhase 21 trial
EnliTISA (Shanghai) Pharmaceutical Co., Ltd. · Acute Respiratory Distress Syndrome (ARDS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.